CN112442028A - RET selective inhibitor and preparation method and application thereof - Google Patents
RET selective inhibitor and preparation method and application thereof Download PDFInfo
- Publication number
- CN112442028A CN112442028A CN201910825867.3A CN201910825867A CN112442028A CN 112442028 A CN112442028 A CN 112442028A CN 201910825867 A CN201910825867 A CN 201910825867A CN 112442028 A CN112442028 A CN 112442028A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- ret
- substituted
- pyridin
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 229940124639 Selective inhibitor Drugs 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 120
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000012453 solvate Substances 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 8
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims description 6
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 4
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005400 Synovial Cyst Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims description 3
- 208000025061 parathyroid hyperplasia Diseases 0.000 claims description 3
- 208000028591 pheochromocytoma Diseases 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 192
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 56
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 52
- -1 Vandertinib Chemical compound 0.000 description 46
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 41
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 41
- 239000002904 solvent Substances 0.000 description 39
- 230000002829 reductive effect Effects 0.000 description 38
- 239000000706 filtrate Substances 0.000 description 35
- 239000000543 intermediate Substances 0.000 description 35
- 238000003756 stirring Methods 0.000 description 32
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 29
- 238000004809 thin layer chromatography Methods 0.000 description 29
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 28
- 235000017557 sodium bicarbonate Nutrition 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
- 239000000284 extract Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 22
- 238000010792 warming Methods 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 101150077555 Ret gene Proteins 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 4
- IIWPRELLGLCAGW-UHFFFAOYSA-N 6-methylsulfanylpyridine-3-carbaldehyde Chemical compound CSC1=CC=C(C=O)C=N1 IIWPRELLGLCAGW-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- PSVPUHBSBYJSMQ-UHFFFAOYSA-N 4-methylsulfonylbenzaldehyde Chemical compound CS(=O)(=O)C1=CC=C(C=O)C=C1 PSVPUHBSBYJSMQ-UHFFFAOYSA-N 0.000 description 3
- PIMQQGJMDMAZGT-UHFFFAOYSA-N 4-methylthiobenzaldehyde Chemical compound CC1=CC=C(C=S)C=C1 PIMQQGJMDMAZGT-UHFFFAOYSA-N 0.000 description 3
- PFEIIXMTROJSBG-UHFFFAOYSA-N 5-methylsulfonylpyridine-2-carbaldehyde Chemical compound CS(=O)(=O)C1=CC=C(C=O)N=C1 PFEIIXMTROJSBG-UHFFFAOYSA-N 0.000 description 3
- CFNNBWFFIJXFND-UHFFFAOYSA-N 6-methylsulfonylpyridine-3-carbaldehyde Chemical compound CS(=O)(=O)C1=CC=C(C=O)C=N1 CFNNBWFFIJXFND-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- UZGMKKWLJRDDDH-UHFFFAOYSA-N [3-cyano-6-[1-(difluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-4-yl]boronic acid Chemical compound N#CC=1C=NN2C=1C(=CC(=C2)C=1C=NN(C=1)C(F)F)B(O)O UZGMKKWLJRDDDH-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000008711 chromosomal rearrangement Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 description 2
- IZSFXIHBVVDTNS-UHFFFAOYSA-N 4-[5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyrazin-2-yl]-6-[1-(difluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound N#CC=1C=NN2C=1C(=CC(=C2)C=1C=NN(C=1)C(F)F)C1=CN=C(C=N1)N1CC2CC(C1)N2 IZSFXIHBVVDTNS-UHFFFAOYSA-N 0.000 description 2
- XDXWLGTWQGSBBL-UHFFFAOYSA-N 4-[6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl]-6-[1-(difluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound C1C2CN(CC1N2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C6=CN(N=C6)C(F)F XDXWLGTWQGSBBL-UHFFFAOYSA-N 0.000 description 2
- XHVFARXNTXWMHH-UHFFFAOYSA-N 4-[6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl]-6-[1-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound N#CC=1C=NN2C=1C(=CC(=C2)C=1C=NN(C=1)C(F)(F)F)C1=CC=C(N=C1)N1CC2CC(C1)N2 XHVFARXNTXWMHH-UHFFFAOYSA-N 0.000 description 2
- TUFNDKNAOWOCLS-UHFFFAOYSA-N 4-[6-(3,8-diazabicyclo[3.2.1]octan-3-yl)pyridin-3-yl]-6-[1-(difluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound C1CC2CN(CC1N2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C6=CN(N=C6)C(F)F TUFNDKNAOWOCLS-UHFFFAOYSA-N 0.000 description 2
- SCVPWLIOZNKCBZ-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-(6-piperazin-1-ylpyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound FC(F)N1C=C(C=N1)C1=CN2N=CC(C#N)=C2C(=C1)C1=CN=C(C=C1)N1CCNCC1 SCVPWLIOZNKCBZ-UHFFFAOYSA-N 0.000 description 2
- ROLFCFWTVKUJMM-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(6-methylsulfanylpyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CSC1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F ROLFCFWTVKUJMM-UHFFFAOYSA-N 0.000 description 2
- MOMWJLFSYPEIOL-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound N#CC=1C=NN2C=1C(O)=CC(=C2)C=1C=NN(C=1)C(F)F MOMWJLFSYPEIOL-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 230000037364 MAPK/ERK pathway Effects 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010071987 RET gene mutation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- UOXFJNMDWKLYQZ-UHFFFAOYSA-N [1-(difluoromethyl)pyrazol-4-yl]boronic acid Chemical compound OB(O)C=1C=NN(C(F)F)C=1 UOXFJNMDWKLYQZ-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001491 aromatic compounds Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JHXKZIFBBRZKDD-UHFFFAOYSA-N tert-butyl 3-[5-[3-cyano-6-[1-(difluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-4-yl]pyrazin-2-yl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound N#CC=1C=NN2C=1C(=CC(=C2)C=1C=NN(C=1)C(F)F)C1=NC=C(N=C1)N1CC2CC(C1)N2C(=O)OC(C)(C)C JHXKZIFBBRZKDD-UHFFFAOYSA-N 0.000 description 2
- WIZOICBGHNDJAZ-UHFFFAOYSA-N tert-butyl 3-[5-[3-cyano-6-[1-(difluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound CC(C)(C)OC(=O)N1C2CC1CN(C2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C6=CN(N=C6)C(F)F WIZOICBGHNDJAZ-UHFFFAOYSA-N 0.000 description 2
- OBAFMTBHULOTER-UHFFFAOYSA-N tert-butyl 3-[5-[3-cyano-6-[1-(difluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]-3,6-diazabicyclo[3.2.1]octane-6-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC2CC1CN(C2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C6=CN(N=C6)C(F)F OBAFMTBHULOTER-UHFFFAOYSA-N 0.000 description 2
- ZYUGMFZMUFNEGZ-UHFFFAOYSA-N tert-butyl 3-[5-[3-cyano-6-[1-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound N#CC=1C=NN2C=1C(=CC(=C2)C=1C=NN(C=1)C(F)(F)F)C1=CC=C(N=C1)N1CC2CC(C1)N2C(=O)OC(C)(C)C ZYUGMFZMUFNEGZ-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- VQEJWKRPRMDRTJ-UHFFFAOYSA-N 2-methylsulfanylpyridine-4-carbaldehyde Chemical compound CSC1=CC(C=O)=CC=N1 VQEJWKRPRMDRTJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZYNNTPMVUWLNCL-UHFFFAOYSA-N 4-[6-[6-[(4-methylsulfonylphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]-6-[1-(trifluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=CC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)(F)F ZYNNTPMVUWLNCL-UHFFFAOYSA-N 0.000 description 1
- ZFTNGWSSHVXSNO-ONEGZZNKSA-N 4-[6-[6-[(E)-4-methoxybut-2-enoyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CN1C=C(C=N1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6C(=O)/C=C/COC ZFTNGWSSHVXSNO-ONEGZZNKSA-N 0.000 description 1
- NZJSGBXNOJOCJI-UHFFFAOYSA-N 4-methylsulfinylbenzaldehyde Chemical compound CS(=O)C1=CC=C(C=O)C=C1 NZJSGBXNOJOCJI-UHFFFAOYSA-N 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- ADUCDHMDEIVHRL-UHFFFAOYSA-N 5-methylsulfanylpyridine-2-carbaldehyde Chemical compound CSC1=CC=C(C=O)N=C1 ADUCDHMDEIVHRL-UHFFFAOYSA-N 0.000 description 1
- ZJCVDANUIBZZIW-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-4-[6-[6-[(4-methylsulfanylphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CN1N=CC(=C1)C=1C=C(C=2N(C1)N=CC2C#N)C=2C=NC(=CC2)N2CC1N(C(C2)C1)CC1=CC=C(C=C1)SC ZJCVDANUIBZZIW-UHFFFAOYSA-N 0.000 description 1
- VJGQIRIOGHLCRB-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-4-[6-[6-[(5-methylsulfonylpyridin-2-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CN1C=C(C=N1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=NC=C(C=C7)S(=O)(=O)C VJGQIRIOGHLCRB-UHFFFAOYSA-N 0.000 description 1
- VPAFNLGGTMQUPH-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-4-[6-[6-[(6-methylsulfonylpyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CN1C=C(C=N1)C2=CN3C(=C(C=N3)C#N)C(=C2)C4=CN=C(C=C4)N5CC6CC(C5)N6CC7=CN=C(C=C7)S(=O)(=O)C VPAFNLGGTMQUPH-UHFFFAOYSA-N 0.000 description 1
- SADVFDOPNINLLT-UHFFFAOYSA-N 6-(3,3-difluoroazetidin-1-yl)-4-[6-[6-[(2-methylsulfonylphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=CC=CC=C1CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)N7CC(C7)(F)F SADVFDOPNINLLT-UHFFFAOYSA-N 0.000 description 1
- FEMFIASYNUVWRJ-UHFFFAOYSA-N 6-(3,3-difluoroazetidin-1-yl)-4-[6-[6-[(3-methylsulfonylphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=CC=CC(=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)N7CC(C7)(F)F FEMFIASYNUVWRJ-UHFFFAOYSA-N 0.000 description 1
- TVRRPLRYQLJYMR-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[5-[6-[(4-methylsulfonylphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyrazin-2-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=CC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(N=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F TVRRPLRYQLJYMR-UHFFFAOYSA-N 0.000 description 1
- UKBFLPCMJUGJBQ-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[4-[(4-methylsulfanylphenyl)methyl]piperazin-1-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CSC1=CC=C(C=C1)CN2CCN(CC2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C6=CN(N=C6)C(F)F UKBFLPCMJUGJBQ-UHFFFAOYSA-N 0.000 description 1
- QCROIEBVPUBGOG-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[4-[(5-methylsulfonylpyridin-2-yl)methyl]piperazin-1-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=CN=C(C=C1)CN2CCN(CC2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C6=CN(N=C6)C(F)F QCROIEBVPUBGOG-UHFFFAOYSA-N 0.000 description 1
- CJPUFBNGXKOODY-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[4-[(6-methylsulfanylpyridin-3-yl)methyl]piperazin-1-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CSC1=NC=C(C=C1)CN2CCN(CC2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C6=CN(N=C6)C(F)F CJPUFBNGXKOODY-UHFFFAOYSA-N 0.000 description 1
- NUDOSCDODHOEQW-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[4-[(6-methylsulfonylpyridin-3-yl)methyl]piperazin-1-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=NC=C(C=C1)CN2CCN(CC2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C6=CN(N=C6)C(F)F NUDOSCDODHOEQW-UHFFFAOYSA-N 0.000 description 1
- ULWCSDWQSTZDLO-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(2-methylsulfanylpyridin-4-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CSC1=NC=CC(=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F ULWCSDWQSTZDLO-UHFFFAOYSA-N 0.000 description 1
- WCQDEKMFRULWGL-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(4-methylsulfanylphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CSC1=CC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F WCQDEKMFRULWGL-UHFFFAOYSA-N 0.000 description 1
- OGJREFVCGPUIFU-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(4-methylsulfinylphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)C1=CC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F OGJREFVCGPUIFU-UHFFFAOYSA-N 0.000 description 1
- MIXBBOLPXDUZLN-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(4-nitrophenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound C1C2CN(CC1N2CC3=CC=C(C=C3)[N+](=O)[O-])C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F MIXBBOLPXDUZLN-UHFFFAOYSA-N 0.000 description 1
- OKYCIBSYAXSOLF-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(5-methylsulfanylpyridin-2-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CSC1=CN=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F OKYCIBSYAXSOLF-UHFFFAOYSA-N 0.000 description 1
- RSXOUNBPHOAVSK-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(5-methylsulfonylpyridin-2-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=CN=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F RSXOUNBPHOAVSK-UHFFFAOYSA-N 0.000 description 1
- NPBXDEXDEYGGAD-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(6-methylsulfanylpyridin-2-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CSC1=CC=CC(=N1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F NPBXDEXDEYGGAD-UHFFFAOYSA-N 0.000 description 1
- IWKQNEXCBUFQMM-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(6-methylsulfonylpyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=NC=C(C=C1)CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F IWKQNEXCBUFQMM-UHFFFAOYSA-N 0.000 description 1
- NEHLULOOKRGFPH-NSCUHMNNSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[6-[(E)-4-methoxybut-2-enoyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC/C=C/C(=O)N1C2CC1CN(C2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)C6=CN(N=C6)C(F)F NEHLULOOKRGFPH-NSCUHMNNSA-N 0.000 description 1
- GYFWDSAIMGHZPW-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[8-[(4-methylsulfonylphenyl)methyl]-3,8-diazabicyclo[3.2.1]octan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CS(=O)(=O)C1=CC=C(C=C1)CN2C3CCC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F GYFWDSAIMGHZPW-UHFFFAOYSA-N 0.000 description 1
- UIYLCACDMRNQPT-UHFFFAOYSA-N 6-[1-(difluoromethyl)pyrazol-4-yl]-4-[6-[8-[(6-methylsulfanylpyridin-3-yl)methyl]-3,8-diazabicyclo[3.2.1]octan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound CSC1=NC=C(C=C1)CN2C3CCC2CN(C3)C4=NC=C(C=C4)C5=CC(=CN6C5=C(C=N6)C#N)C7=CN(N=C7)C(F)F UIYLCACDMRNQPT-UHFFFAOYSA-N 0.000 description 1
- IFUVDUFAFVWZOT-UHFFFAOYSA-N 6-bromo-4-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound BrC=1C=C(C=2N(C=1)N=CC=2C#N)O IFUVDUFAFVWZOT-UHFFFAOYSA-N 0.000 description 1
- QVYAMTAWGBAROE-UHFFFAOYSA-N 6-methylsulfanylpyridine-2-carbaldehyde Chemical compound CSC1=CC=CC(C=O)=N1 QVYAMTAWGBAROE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100026376 Artemin Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- OSITUWYNKYNJQG-UHFFFAOYSA-N CC(C1)(C=CC=CN1C1=CN2N=CC(C#N)=C2C(C2=CC=C(N3CC(C4)N(CC5=CC(S(C)(=O)=O)=CC=C5)C4C3)N=C2)=C1)O Chemical compound CC(C1)(C=CC=CN1C1=CN2N=CC(C#N)=C2C(C2=CC=C(N3CC(C4)N(CC5=CC(S(C)(=O)=O)=CC=C5)C4C3)N=C2)=C1)O OSITUWYNKYNJQG-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000785776 Homo sapiens Artemin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108091008551 RET receptors Proteins 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101150051175 TRIM33 gene Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YGIFRCXNFFWLPD-UHFFFAOYSA-N [1-(trifluoromethyl)pyrazol-4-yl]boronic acid Chemical compound OB(O)C=1C=NN(C(F)(F)F)C=1 YGIFRCXNFFWLPD-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- UNXISIRQWPTTSN-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].[B].CC(C)(O)C(C)(C)O UNXISIRQWPTTSN-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- DGFDWLQDQXKDKM-UHFFFAOYSA-N tert-butyl 3-(5-bromopyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate Chemical compound BrC1=CC=C(N=C1)N1CC2CCC(C1)N2C(=O)OC(C)(C)C DGFDWLQDQXKDKM-UHFFFAOYSA-N 0.000 description 1
- ZNOQWHYEPWCDNU-UHFFFAOYSA-N tert-butyl 3-(5-chloropyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound ClC=1N=CC(=NC=1)N1CC2N(C(C1)C2)C(=O)OC(C)(C)C ZNOQWHYEPWCDNU-UHFFFAOYSA-N 0.000 description 1
- SQXWMRZXUURMIY-UHFFFAOYSA-N tert-butyl 3-[5-(3-cyano-6-hydroxypyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound C(#N)C=1C=NN2C=1C(=CC(=C2)O)C=1C=CC(=NC=1)N1CC2N(C(C1)C2)C(=O)OC(C)(C)C SQXWMRZXUURMIY-UHFFFAOYSA-N 0.000 description 1
- DSLVSFMWCDGZIL-UHFFFAOYSA-N tert-butyl 4-(5-bromopyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Br)C=N1 DSLVSFMWCDGZIL-UHFFFAOYSA-N 0.000 description 1
- ZJTGMROGDILDST-UHFFFAOYSA-N tert-butyl 4-[5-[3-cyano-6-[1-(difluoromethyl)pyrazol-4-yl]pyrazolo[1,5-a]pyridin-4-yl]pyridin-2-yl]piperazine-1-carboxylate Chemical compound C(#N)C=1C=NN2C=1C(=CC(=C2)C=1C=NN(C=1)C(F)F)C=1C=CC(=NC=1)N1CCN(CC1)C(=O)OC(C)(C)C ZJTGMROGDILDST-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides RET selective inhibitors, methods of preparation and uses thereof; the present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates, polymorphs, or isomers thereof, pharmaceutical compositions comprising these compounds, and the use of such compounds in the treatment of RET related diseases.
Description
Technical Field
The present invention relates to compounds which selectively inhibit the activity of RET proteins, to processes for their preparation and to their use in pharmaceutical compositions.
Background
RET is a protooncogene, located on chromosome 10. The RET protein encoded by the RET gene is a Receptor Tyrosine Kinase (RTK) present in cell membranes, belongs to a member of the cadherin superfamily, and plays an important role in the normal development of the peripheral sympathetic and parasympathetic nervous systems of the brain, the production of calcitonin by thyroid C cells, and is also essential for the thyroid and lung, as well as hematopoietic progenitor cells and other tissues (Nat. Rev. cancer 2014; 14 (3): 173-86.).
The domain composition of RET proteins is identical to that of other protein tyrosine kinases, and contains a typical extracellular domain, a transmembrane segment, followed by an intracellular membrane proximal segment, a kinase domain, and a carboxy-terminal tail. The extracellular domain contains four cadherin-like domain repeats of about 110 amino acid residues (CD1/2/3/4) and a cysteine-rich segment of about 150 amino acid residues immediately adjacent to the transmembrane segment, with extracellular Ca present between CD2 and CD32+ binding site (J.biol.CHEm.2001; 276 (38): 35808-35817).
RET is the only receptor protein tyrosine kinase with a cadherin-like domain. Although having the same domain composition as other protein tyrosine kinases, the activation mechanism of RET differs, and its activation requires an additional GDNF family receptor (GDNF/NTRN/ARTN/PSP) -GFR co-receptor (GFR 1/2/3/4). Members of the GDNF family typically exist as disulfide-linked homodimers that interact with two GFR complexes to form binary complexes that interact with two RET receptors, eventually forming a hexameric complex consisting of two receptors, two co-receptors, and a ligand dimer (nat. rev. cancer 2014; 14 (3): 173-86). RET is in a non-phosphorylated, inactive state in the absence of ligand-mediated stimulation. When the RET protein binds to its ligand, GDNF, it causes phosphorylation of the RET protein receptor and brings RET into an activated state. Activated RET will phosphorylate its substrate, resulting in activation of downstream signaling pathways. The signaling pathways involved in the RET protein include the PI3K-AKT-mTOR pathway and the RAS-RAF-MEK-ERK pathway. The PI3K-AKT-mTOR pathway is involved in cell survival, while the RAS-RAF-MEK-ERK pathway is involved in cell proliferation. Therefore, RET protein has a certain role in Cell survival, migration and proliferation (Cell 2010; 141 (7): 1117-1134; Cell. Signal. 2014; 26 (8): 1743-1752).
The mutations occurring in the RET gene encoding RET protein kinase include activation point mutation and gene fusion, which lead to excessive activation of RET signaling pathway and uncontrolled proliferation of cells, resulting in diseases such as malignant tumors. Chromosomal rearrangement of ret gene is associated with the occurrence of thyroid papillary carcinoma, and the chromosomal rearrangement may lead to a break in the middle of the ret gene, and the kinase domain of the ret gene is fused with more than ten different genes, such as kif5b, cccc 6, ncoa4, etc., to form a fusion gene that drives tumor proliferation (Transl Lung Cancer Res.2015; 4 (2): 156-. In 5% -40% of Papillary Thyroid Carcinomas (PTCs) of the thyroid, ret gene fusion is found, and ret gene rearrangement in papillary thyroid carcinomas is related to ionizing radiation, namely, the cancers occur due to nuclear radiation in the environment and the like. The fusion of ret genes resulting from chromosomal rearrangements also occurs in non-small cell lung cancer (NSCLC), with the frequency of ret gene fusions in NSCLC being approximately 1% -2%, and fusion partner genes for the four ret genes are currently identified as kif5b, cccd 6, ncoa4, and trim33, respectively, with the most common form of fusion kif5b-ret (Oncoloist.2013; 18 (7): 865-875). Point mutations in the ret gene, such as those caused by activation of the ret gene by mutations at the V804M, M918T alleles, also lead to tumorigenesis, mainly in multiple endocrine tumors (MEN2A, MEN2B) and Medullary Thyroid Carcinoma (MTC) (Ann Oncol.2016; 27 (7): 1286-1291). Germ cell ret gene mutations, occurring in almost all hereditary medullary thyroid cancers, comprise multiple endocrine adenomatosis type 2. In acquired medullary thyroid carcinoma, ret gene mutations also occur in 50% of patients (Ann Oncol.2016; 27 (7): 1286-1291).
Currently, in the United states, the number of new cases of tumors bearing RET mutations or RET fusion proteins is estimated to be about 10,000 per year, which is about the same as the incidence of chronic myelogenous leukemia (PHarmalogic ResearcH H2018; 128: 1-17). Several drugs against RET have been FDA approved for the treatment of cancer: cabozantinib, Vandertinib, Lenvatinib, Sorafenib, Alectonib, etc., which are multi-kinase inhibitors with anti-RET activity, have relatively poor clinical effects for RET targeted therapy and are accompanied by toxic side effects due to significant inhibition of other kinases such as vascular endothelial growth factor receptor 2(VEGFR2) (Nat Rev Clin Oncol.2018; 15 (3): 151-167). Therefore, the development of highly selective RET inhibitors has attracted research interest from numerous pharmaceutical companies, and the development of specific RET inhibitors has become an emerging therapeutic approach to improve the therapeutic efficacy of RET-driven cancers.
Disclosure of Invention
The invention provides a selective inhibitor of RET, which is a compound represented by a general formula (I) or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof. The invention also provides a series of compounds represented by the general formula (I) and pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, pharmaceutical compositions containing the compounds, and methods of treating diseases using the compounds.
In one aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof:
(I)
wherein,
x and Y are each independently selected from CH and N;
a is selected from 5-6 membered heteroaromaticRadical, 3-to 12-membered heterocyclyl, -O-C1-6Alkyl, -S-C1-6Alkyl and-SO2-C1-6Alkyl, said heteroaryl and heterocyclyl being each optionally substituted by C1-6Alkyl, -CN, -OH, -NR5R6Halogen, -O-C1-6Alkyl, -S-C1-6Alkyl, or-SO2-C1-6Alkyl substitution, said C1-6Alkyl may optionally be substituted by-OH, halogen, or- (CO) N (CH)3)2Is substituted, and R5And R6Each independently selected from H and C1-6An alkyl group;
R1、R1’、R2and R2' independently of one another are H or C1-6Alkyl, or R1And R1' one of the compounds with R2And R2One of' may be taken together to form a bond or- (CH)2)m-;
R8Each independently selected from H, C1-6Alkyl, -O-C1-6Alkyl and- (CH)2)m-O-C1-6An alkyl group;
ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl, each of which may optionally be substituted by-O-C1-6Alkyl, -S-C1-6Alkyl, -SO-C1-6Alkyl, or-SO2-C1-6Alkyl substitution;
each M is independently selected from 1 and 2;
n is selected from 0, 1 and 2;
in some embodiments of the invention, A is selected from 5-6 membered heteroaryl and 3-12 membered heterocyclyl, each of which may be optionally substituted with C1-6Alkyl, -CN, -OH, -NR5R6Halogen, -O-C1-6Alkyl, -S-C1-6Alkyl, or-SO2-C1-6Alkyl substitution, said C1-6Alkyl may optionally be substituted by-OH, halogen, or- (CO) N (CH)3)2Is substituted, and R5And R6Each independently selected from H and C1-6An alkyl group;
in some embodiments of the invention, A is selected from 5-6 membered heteroaryl and 4-9 membered heterocyclyl, each of which may be optionally substituted with C1-6Alkyl, -CN, -OH, -NR5R6Halogen, -O-C1-6Alkyl, -S-C1-6Alkyl, or-SO2-C1-6Alkyl substitution, said C1-6Alkyl may optionally be substituted by-OH, halogen, or- (CO) N (CH)3)2Is substituted, and R5And R6Each independently selected from H and C1-6An alkyl group;
in some embodiments of the invention, the compounds of the invention are selected from:
or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof.
Yet another aspect of the present invention is directed to a pharmaceutical composition comprising a compound of formula (I) of the present invention, or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof, and a pharmaceutically acceptable carrier;
in another aspect, the present invention provides a method of treating a RET-associated disease, said method comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof, or a combination thereof; in some embodiments, the RET-associated disease is lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine tumors of type 2A or 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal ganglion cell tumor, and cervical cancer, preferably RET-fused body lung cancer or medullary thyroid cancer, more preferably small cell lung cancer, non-small cell lung cancer, bronchiolar lung cancer, or lung adenocarcinoma;
in some embodiments of the invention, the subject to which the invention relates is a mammal including a human;
in another aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof, in the manufacture of a medicament for the treatment of a RET-associated disease; in some embodiments, the RET-associated disease is lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine tumors of type 2A or 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal ganglion cell tumor, or cervical cancer, preferably RET fusogenic lung cancer or medullary thyroid cancer, more preferably small cell lung cancer, non-small cell lung cancer, or bronchiolar lung cancer or lung adenocarcinoma.
Detailed Description
Exemplary embodiments utilizing the principles of the present invention are set forth in the following detailed description of the invention. The features and advantages of the present invention may be better understood by reference to the following summary.
It should be understood that the scope of the various aspects of the invention is defined by the claims and that methods and structures within the scope of these claims and their equivalents are intended to be covered thereby.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. All patents, patent applications, and publications cited herein are incorporated by reference in their entirety unless otherwise indicated.
It is to be understood that both the foregoing general description and the following detailed description are exemplary, explanatory and are not restrictive of any inventive subject matter. The use of the singular forms also includes the plural unless specifically stated otherwise. The use of "or", "or" means "and/or" unless stated otherwise. Furthermore, the term "comprising" as well as other forms, such as "includes," "including," and "containing," are not limiting.
Certain chemical terms
The terms "optional," "optional," or "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, "optionally substituted alkyl" means "unsubstituted alkyl" or "substituted alkyl". And, optionally substituted groups may be unsubstituted (e.g.: CH)2CH3) Fully substituted (e.g.: -CF2CF3) Monosubstituted (e.g.: -CH2CH2F) Or any level between mono-and fully substituted (e.g.: -CH2CHF2、-CF2CH3、-CFHCHF2Etc.). It will be appreciated by those skilled in the art that any group containing one or more substituents will not incorporate any substitution or substitution pattern which is sterically impossible and/or cannot be synthesized.
Unless otherwise indicated, conventional methods within the skill of the art are employed, such as mass spectrometry, nuclear magnetism, high performance liquid chromatography, infrared and ultraviolet/visible spectroscopy, and pharmacological methods. Unless specific definitions are set forth, the nomenclature used herein in the analytical chemistry, organic synthetic chemistry, and pharmaceutical and medicinal chemistry, as well as the laboratory procedures and techniques, are those known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and treatment of patients. For example, the reaction and purification can be carried out using the instructions of the kit from the manufacturer, or according to the methods known in the art or the instructions of the present invention. The techniques and methods described above can generally be practiced according to conventional methods well known in the art, as described in various general and more specific documents referred to and discussed in this specification. In the present specification, groups and substituents thereof may be selected by one skilled in the art to provide stable moieties and compounds.
When a substituent is described by a general formula written from left to right, the substituent also includes chemically equivalent substituents obtained when the formula is written from right to left. For example, -CH2O-is equivalent to-OCH2-。
As used herein, the terms "group", "chemical group" or "chemical group" refer to a particular portion or functional group of a molecule. Chemical groups are often considered as chemical entities embedded in or attached to a molecule.
Some of the chemical groups named herein may be referred to by a shorthand notation for the total number of carbon atoms. E.g. C1-C6Alkyl describes an alkyl group, as defined below, having a total of 1 to 6 carbon atoms. The total number of carbon atoms indicated by shorthand notation does not include carbon atoms on possible substituents.
The terms "halogen", "halo" or "halide" refer to bromine, chlorine, fluorine or iodine.
The terms "aromatic", "aromatic ring", "aromatic" and "aromatic-cyclic" as used herein refer to a planar ring portion of one or more rings having a delocalized electron-conjugated system of 4n +2 electrons, where n is an integer. The aromatic ring may be formed of 5, 6, 7, 8, 9 or more atoms. The aromatic compound may be optionally substituted and may be monocyclic or fused-ring polycyclic. The term aromatic compound includes all carbocyclic rings (e.g., benzene rings) and rings containing one or more heteroatoms (e.g., pyridine).
The term "heteroatom" or "hetero" as used herein alone or as part of another component refers to atoms other than carbon and hydrogen. The heteroatoms are independently selected from oxygen, nitrogen, sulfur, phosphorus, silicon, selenium and tin, but are not limited to these atoms. In embodiments where two or more heteroatoms are present, the two or more heteroatoms may be the same as each other, or some or all of the two or more heteroatoms may be different from each other.
The terms "fused" or "fused ring" as used herein, alone or in combination, refer to a cyclic structure in which two or more rings share one or more bonds.
The term "spiro" or "spirocyclic" as used herein, alone or in combination, refers to a cyclic structure in which two or more rings share one or more atoms.
The term "alkyl" as used herein alone or as part of another component (e.g., monoalkylamino) refers to an optionally substituted straight or optionally substituted branched chain monovalent saturated hydrocarbon having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms, attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, 2-methylhexyl, 3 methylhexyl, n-octyl, n-nonyl, n-decyl, and the like.
The term "cycloalkyl" as used herein alone or as part of another ingredient refers to a stable monovalent non-aromatic monocyclic or polycyclic hydrocarbon group containing only carbon and hydrogen atoms, and may include fused, spiro or bridged ring systems containing from 3 to 15 ring-forming carbon atoms, preferably from 3 to 10 ring-forming carbon atoms, more preferably from 3 to 8 ring-forming carbon atoms, which may or may not be saturated, attached to the rest of the molecule by single bonds. Non-limiting examples of "cycloalkyl" include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
The terms "heterocyclyl", "heterocycloalkyl", "heterocycle", as used herein alone or as part of another ingredient, refer to a stable 3-18 membered monovalent non-aromatic ring comprising 2-12 carbon atoms, 1-6 heteroatoms selected from nitrogen, oxygen and sulfur. Unless otherwise specified, a heterocyclyl group may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may contain fused, spiro or bridged ring systems, the nitrogen, carbon or sulfur of the heterocyclyl group may optionally be oxidized, the nitrogen atom may optionally be quaternized, and the heterocyclyl group may be partially or fully saturated. The heterocyclic group may be attached to the rest of the molecule through a single bond via a carbon or heteroatom in the ring. The heterocyclic group containing fused rings may contain one or more aromatic or heteroaromatic rings, provided that the atoms on the non-aromatic ring are attached to the rest of the molecule. For purposes of this application, a heterocyclyl group is preferably a stable 4-11 membered monovalent non-aromatic monocyclic or bicyclic ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, and more preferably a stable 4-8 membered monovalent non-aromatic monocyclic ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur. Non-limiting examples of heterocyclyl groups include azepanyl, azetidinyl, decahydroisoquinolinyl, dihydrofuranyl, indolinyl, dioxolanyl, 1-dioxo-thiomorpholinyl, imidazolidinyl, imidazolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazinyl, piperazinyl, piperidinyl, 4-piperidinonyl, pyranyl, pyrazolidinyl, pyrrolidinyl, quinolizinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl and the like.
The term "polymorph" or "polymorph" as used herein means that the compounds of the present invention have multiple lattice morphologies. Some of the compounds of the present invention may have more than one crystal form, and the present invention encompasses all polymorphic forms or mixtures thereof.
Intermediate compounds of the present invention and polymorphs thereof are also within the scope of the present invention.
Unless otherwise specified, the compounds of the present invention contain olefinic double bonds including E and Z isomers.
It is understood that the compounds of the present invention may contain asymmetric centers. These asymmetric centers may independently be in the R or S configuration. It will be apparent to those skilled in the art that some of the compounds of the present invention may also exhibit cis-trans isomerism. It is to be understood that the compounds of the present invention include their individual geometric and stereoisomers as well as mixtures thereof, including racemic mixtures. These isomers may be separated from their mixtures by carrying out or modifying known methods such as chromatographic techniques and recrystallization techniques, or they may be prepared separately from the appropriate isomers of their intermediates.
The term "pharmaceutically acceptable salts" as used herein includes both acid and base salts.
"pharmaceutically acceptable acid addition salts" refers to those salts formed with inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or organic acids such as, but not limited to, acetic acid, 2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, capric acid, caproic acid, carbonic acid, cinnamic acid, citric acid, and the like, which retain the biological potency and properties of the free base of the compound, which are not biologically or otherwise undesirable. "pharmaceutically acceptable salt to be added to base" refers to those salts that retain the biological potency and properties of the free acid of the compound and are not biologically or otherwise undesirable. These salts are prepared by reacting the free acid with an inorganic or organic base. Salts formed by reaction with an inorganic base include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Preferred inorganic salts are ammonium, sodium, potassium, calcium, and manganese salts.
Salt-forming organic bases include, but are not limited to, primary, secondary, tertiary, cyclic amines, and the like, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, ethanolamine, dicyclohexylamine, ethylenediamine, purine, piperazine, piperidine, choline, caffeine, and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
Crystallization often produces solvates of the compounds of the present invention. The term "solvate" as used herein refers to a combination of one or more molecules of the compound of the present invention and one or more molecules of a solvent.
The solvent may be water, in which case the solvate is a hydrate. In addition, an organic solvent may be used. Thus, the compounds of the present invention may exist as hydrates, including monohydrate, dihydrate, hemihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms. The compounds of the present invention may be true solvates, but in other cases, the compounds of the present invention may also retain water only by chance or a mixture of water and some other solvent. The compounds of the invention may be reacted in a solvent or precipitated or crystallized in a solvent. Solvates of the compounds of the invention are also included within the scope of the invention.
The term "pharmaceutical composition" as used herein refers to a formulation mixed with a compound of the present invention and a vehicle generally accepted in the art for delivering biologically active compounds to a mammal, such as a human. Such media comprise all pharmaceutically acceptable carriers.
As used herein, the term "acceptable" in reference to a formulation, composition or ingredient means that there is no lasting deleterious effect on the overall health of the subject being treated.
The term "pharmaceutically acceptable" as used herein refers to a substance (e.g., carrier or diluent) that does not affect the biological activity or properties of the compounds of the present invention and is relatively non-toxic, i.e., the substance can be administered to an individual without causing an adverse biological response or interacting in an adverse manner with any of the components contained in the composition.
"pharmaceutically acceptable carriers" include, but are not limited to, adjuvants, carriers, excipients, adjuvants, deodorants, diluents, preservatives, dyes/colorants, flavor enhancers, surfactants and wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, solvents, or emulsifiers that have been approved by the relevant governmental authorities for use in humans and domestic animals.
The terms "subject," "patient," "subject" or "individual" as used herein refer to an individual having a disease, disorder or condition, and the like, including mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class mammalia: humans, non-human primates (e.g., chimpanzees and other apes and monkeys); livestock, such as cattle, horses, sheep, goats, pigs; domestic animals such as rabbits, dogs, and cats; laboratory animals, including rodents, such as rats, mice, and guinea pigs, and the like. Examples of non-human mammals include, but are not limited to, birds, fish, and the like. In one embodiment related to the methods and compositions provided herein, the mammal is a human.
The term "treatment" as used herein refers to the treatment of a disease or condition associated with a mammal, particularly a human, and includes
(i) Preventing the development of a disease or condition in a mammal, particularly a mammal that has previously been exposed to the disease or condition but has not been diagnosed as having the disease or condition;
(ii) inhibiting the disease or disorder, i.e., controlling its development;
(iii) alleviating the disease or condition, i.e., causing regression of the disease or condition;
(iv) relieving symptoms caused by the disease or disorder.
The terms "disease" and "condition" as used herein may be used interchangeably and may have different meanings, as certain specific diseases or conditions have no known causative agent (and therefore the cause of the disease is not yet clear) and therefore are not considered as a disease but can be considered as an unwanted condition or syndrome, with more or less specific symptoms being confirmed by clinical researchers.
The terms "effective amount," "therapeutically effective amount," or "pharmaceutically effective amount" as used herein, refer to an amount of at least one agent or compound that is sufficient to alleviate one or more symptoms of the disease or disorder being treated to some extent after administration. The result may be a reduction and/or alleviation of signs, symptoms, or causes, or any other desired change in a biological system. For example, an "effective amount" for treatment is the amount of a composition comprising a compound disclosed herein that is clinically necessary to provide a significant remission effect of the condition. An effective amount suitable in any individual case can be determined using techniques such as a dose escalation assay.
The terms "administering," "administration," "administering," and the like as used herein refer to a method capable of delivering a compound or composition to a desired site for biological action. These methods include, but are not limited to, oral routes, via the duodenal route, parenteral injection (including intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), topical administration, and rectal administration. In preferred embodiments, the compounds and compositions discussed herein are administered orally.
Preparation of the Compounds of the invention
The following reaction scheme illustrates the process for preparing the compounds of the present invention.
It will be appreciated that in the following description, combinations of substituents and/or variables of the formula are permitted only in the context of forming stable compounds.
It will also be appreciated by those skilled in the art that in the schemes described below, the functional groups of the intermediate compounds may need to be protected by suitable protecting groups. These functional groups include hydroxyl, amino, mercapto and carboxyl groups. Suitable hydroxyl protecting groups include trialkylsilyl or diarylalkylsilyl groups (e.g., tert-butylmethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable amino, amidino and guanidine protecting groups include t-butyloxycarbonyl, benzyloxycarbonyl and the like. Suitable protecting groups for the thiol group include-C (O) -R '(R' represents an alkyl, aryl or arylalkyl group), p-methoxybenzyl, trityl, and the like. Suitable carboxyl protecting groups include alkyl, aryl or arylalkyl esters. Protecting groups may be added or removed by standard techniques known to those skilled in the art.
Examples
The following non-limiting examples are illustrative only and do not limit the invention in any way.
Unless otherwise indicated, temperatures are in degrees celsius. Reagents were purchased from commercial suppliers such as national drug group chemical reagents beijing ltd, Alfa Aesar (Alfa Aesar), or beijing carbofuran technologies ltd, and these reagents were used directly without further purification unless otherwise specified.
Unless otherwise stated, the following reactions are carried out at room temperature, in anhydrous solvents, under positive pressure of nitrogen or argon, or using a drying tube; the reaction bottle is provided with a rubber diaphragm so as to add the substrate and the reagent through an injector; glassware was dried and/or heat dried.
Unless otherwise stated, column chromatography purification was performed using 200-300 mesh silica gel from Qingdao oceanic plants; preparation of thin-layer chromatography silica gel precast slab (HSGF254) produced by Nicoti chemical industry research institute was used; MS is measured by a THERMOL LCQ FREet model (ESI) liquid chromatography-mass spectrometer; the optical rotation was measured by using an SGW-3 automatic polarimeter, Shanghai Spanish Meter, Ltd.
Nuclear magnetic data (1H NMR) was run at 400MHz using a Varian instrument. The solvent used for nuclear magnetic data is CDCl3、CD3OD、D2O, DMSO-d6, based on tetramethylsilane (0.00ppm) or based on residual solvent (CDCl)3:7.26ppm;CD3OD:3.31ppm;D2O: 4.79 ppm; d 6-DMSO: 2.50 ppm). When indicating the diversity of the peak shapes, the following abbreviations represent the different peak shapes: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), dd (doublet of doublets), dt (doublet of triplets). If the coupling constant is given, it is given in Hertz (Hz).
Abbreviations:
Pd2(dba)3 | tris (dibenzylideneacetone) dipalladium |
(±)BINAP | (±) -2, 2 '-bis (diphenylphosphino) -1, 1' -binaphthalene |
Pd(dppf)Cl2 | 1, 1' -bis (diphenylphosphino) ferrocene palladium dichloride |
TEA | Triethylamine |
TFA | Trifluoroacetic acid |
NaBH(OAc)3 | Sodium triacetoxyborohydride |
DMSO | Dimethyl sulfoxide |
KOAc | Potassium acetate |
Toluene | Toluene |
K2CO3 | Potassium carbonate |
Pd(PPH3)4 | Tetratriphenylphosphine palladium |
Cs2CO3 | Cesium carbonate |
Intermediate 21: synthesis of 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (1-difluoromethyl-1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Step 1: 3- (5- (3-cyano-6- (trifluoromethanesulfonate) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester
Tert-butyl 3- (5- (3-cyano-6-hydroxypyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylate (432mg) was dissolved in DMF (20mL), to which DIEA (260mg) was added, followed by N-phenylbis (trifluoromethanesulfonyl) imide (400 mg). After stirring at room temperature for 2 hours, the mixture was poured into water (100mL), and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: petroleum ether: ethyl acetate ═ 2: 1 (V: V)) to give the objective compound. (450mg)
Step 2: 3- (5- (3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester
3- (5- (3-cyano-6- (trifluoromethanesulfonate) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester (282mg), 1-difluoromethylpyrazole-4-boronic acid (100mg), tetratriphenylphosphine palladium (55mg) and potassium carbonate (139mg) were successively added to a flask containing dioxane and water (50mL, volume ratio 5: 1), and the reaction flask was replaced with nitrogen three times. Heat to 80 ℃ and stir overnight. After cooling to room temperature, the reaction mixture was poured into water (150mL), followed by extraction with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the objective compound (200 mg).
And step 3: 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Tert-butyl 3- (5- (3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylate (200mg) was added at room temperature.
Dissolved in methylene chloride (20mL), trifluoroacetic acid (4mL) was added, the mixture was stirred for 2 hours, and the solvent was evaporated under reduced pressure in vacuo. Saturated aqueous sodium bicarbonate was added to the residue until the system was weakly basic, and the resulting solid of the objective compound (130mg) was filtered and dried.
Intermediate 22: synthesis of 4- (6- (3, 8-diazabicyclo [3.2.1] octan-3-yl) pyridin-3-yl) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Step 1: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4-hydroxypyrazolo [1, 5-a ] pyridine-3-carbonitrile
6-bromo-4-hydroxypyrazolo [1, 5-a ] pyridine-3-carbonitrile (238mg), 1-difluoromethylpyrazole-4-boronic acid (200mg), palladium tetratriphenylphosphine (110mg) and potassium carbonate (278mg) were successively added to a flask containing dioxane and water (50mL, volume ratio 5: 1), and the reaction flask was replaced with nitrogen gas three times. Heat to 80 ℃ and stir overnight. After cooling to room temperature, the reaction mixture was poured into water (150mL), followed by extraction with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the objective compound (250 mg).
Step 2: 3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl trifluoromethanesulfonate
6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4-hydroxypyrazolo [1, 5-a ] pyridine-3-carbonitrile (250mg) was dissolved in DMF (20mL), to which DIEA (300mg) was added, followed by N-phenylbis (trifluoromethanesulfonyl) imide (400 mg). After stirring at room temperature for 2 hours, the mixture was poured into water (50mL), and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: petroleum ether: ethyl acetate 1: 1 (V: V)) to obtain the objective compound. (300mg)
And step 3: 3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-ylboronic acid
3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl trifluoromethanesulfonate (300mg), pinacol diboron (254mg), [1, 1' -bis (diphenylphosphino) ferrocene ] dichloropalladium (73mg) and potassium acetate (196mg) were added to dried dioxane (30mL) under nitrogen, heated to 90 ℃ and stirred overnight. Cooling to room temperature, filtering, washing a filter cake with dichloromethane, and evaporating a filtrate under reduced pressure to obtain a crude target compound which is directly used for the next reaction.
And 4, step 4: 3- (5- (3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.2.1] octane-6-carboxylic acid tert-butyl ester
The boric acid (150mg) obtained above, tert-butyl 3- (5-bromopyridin-2-yl) -3, 8-diazabicyclo [3.2.1] octane-8-carboxylate (183mg), palladium tetratriphenylphosphine (50mg) and potassium carbonate (139mg) were sequentially added to a flask containing dioxane and water (50mL, volume ratio 5: 1), and the reaction flask was replaced with nitrogen gas three times. Heat to 80 ℃ and stir overnight. After cooling to room temperature, the reaction mixture was poured into water (150mL), followed by extraction with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the objective compound (250 mg).
And 5: 4- (6- (3, 8-diazabicyclo [3.2.1] octan-3-yl) pyridin-3-yl) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Tert-butyl 3- (5- (3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.2.1] octane-6-carboxylate (250mg) was added at room temperature
Dissolved in methylene chloride (20mL), trifluoroacetic acid (5mL) was added, the mixture was stirred for 1 hour, and the solvent was evaporated under reduced pressure in vacuo. To the residue was added a saturated aqueous sodium hydrogencarbonate solution until the system became weakly basic, and the resulting solid of the objective compound (180mg) was filtered and dried.
Intermediate 23: synthesis of 4- (5- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyrazin-2-yl) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Step 1: 3- (5- (3-cyano-6- (1-difluoromethyl-1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyrazin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester
Reacting 3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-ylboronic acid
(303mg) tert-butyl 3- (5-chloropyrazin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylate (250mg) from intermediate 4, step 2 was dissolved in a mixed solution of dioxane and water (5: 1) (50mL), and tetratriphenylphosphine palladium (110mg) and anhydrous potassium carbonate powder (278mg) were added in this order under nitrogen. Then, the reaction mixture was stirred at 85 ℃ for 2 hours, cooled to room temperature, poured into water (150mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate 2: 1 (V: V)) to give the title compound (400 mg).
Step 2: 4- (5- (3, 6-diaza-bicyclo [3.1.1] heptan-3-yl) pyrazin-2-yl) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Trifluoroacetic acid (5mL) was slowly added dropwise to a dichloromethane (20mL) solution of tert-butyl 3- (5- (3-cyano-6- (1-difluoromethyl-1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyrazin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylate (400mg) obtained in step 1 at 0 ℃, and after completion of the addition, the mixture was warmed to room temperature and stirred for 1H. The reaction solution was concentrated, and then saturated aqueous sodium bicarbonate solution was added to adjust the pH to a weak alkaline, and the resulting solid was filtered and dried to obtain the title compound (240 mg).
Intermediate 24: synthesis of 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (piperazin-1-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Step 1: 4- (5- (3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) piperazine-1-carboxylic acid tert-butyl ester
3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-ylboronic acid (303mg) and tert-butyl 4- (5-bromopyridin-2-yl) piperazine-1-carboxylate (342mg) were dissolved in a mixed solution of dioxane and water (5: 1) (50mL), and tetratriphenylphosphine palladium (110mg) and anhydrous potassium carbonate powder (278mg) were sequentially added under nitrogen protection. Then, the reaction mixture was stirred at 85 ℃ for 2 hours, cooled to room temperature, poured into water (150mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate 2: 1 (V: V)) to give the title compound (410 mg).
Step 2: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (piperazin-1-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Trifluoroacetic acid (5mL) was slowly added dropwise to a solution of tert-butyl 4- (5- (3-cyano-6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) piperazine-1-carboxylate (410mg) obtained in step 1 in dichloromethane (20mL) at 0 ℃, and after completion of the addition, the mixture was warmed to room temperature and stirred for 1H. The reaction solution was concentrated, and then saturated aqueous sodium bicarbonate solution was added to adjust the pH to a weak alkaline, and the resulting solid was filtered and dried to obtain the title compound (220 mg).
Intermediate 25: synthesis of 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (1-trifluoromethyl-1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Step 1: 3- (5- (3-cyano-6- (1- (trifluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester
3- (5- (3-cyano-6- (trifluoromethanesulfonate) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester (282mg), 1-trifluoromethylpyrazole-4-boronic acid (110mg), tetratriphenylphosphine palladium (50mg) and potassium carbonate (139mg) were sequentially added to a flask containing dioxane and water (40mL, volume ratio 5: 1), and the reaction flask was replaced with nitrogen three times. Heat to 80 ℃ and stir overnight. After cooling to room temperature, the reaction mixture was poured into water (150mL), followed by extraction with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the objective compound (170 mg).
Step 2: synthesis of 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (1-trifluoromethyl-1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Tert-butyl 3- (5- (3-cyano-6- (1- (trifluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylate (170mg) was added at room temperature
Dissolved in methylene chloride (20mL), trifluoroacetic acid (4mL) was added, the mixture was stirred for 2 hours, and the solvent was evaporated under reduced pressure in vacuo. Saturated aqueous sodium bicarbonate was added to the residue until the system was weakly basic, and the resulting solid of the objective compound (120mg) was filtered and dried.
Example 59: 6- (1-methyl-1H-pyrazol-4-yl) -4- (6- (6- (4- (methylthio) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 2(40mg) was dissolved in THF (10mL) at 0 deg.C, and 4-methylthiobenzaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extracts were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (30 mg).
1H NMR(400MHz,CDCl3)δ8.66(1H,d,J=1.2Hz),8.45(1H,d,J=2.4Hz),8.27(1H,s),7.85(1H,dd,J=8.4Hz,2.4Hz),7.80(1H,s),7.70(1H,s),7.50(2H,d,J=8.0Hz),7.43(1H,d,J=1.2Hz),7.24(2H,d,J=8.0Hz),6.73(1H,d,J=8.4Hz),4.18-4.32(2H,m),3.80-4.09(9H,m),3.16-3.30(1H,m),2.47(3H,s),1.82-1.89(1H,m)。
Example 60: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (6- ((6- (methylthio) pyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (10mL) at 0 deg.C, and 6- (methylthio) nicotinaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (27 mg).
1H NMR(400MHz,CDCl3)δ8.72(1H,d,J=1.6Hz),8.44(1H,d,J=2.4Hz),8.41(1H,d,J=2.0Hz),8.31(1H,s),8.14(1H,s),7.97(1H,s),7.82(1H,dd,J=8.8Hz,2.4Hz),7.64-7.70(1H,m),7.43(1H,d,J=1.6Hz),7.25(1H,t,J=60.4Hz),7.16(1H,d,J=8.4Hz),6.71(1H,d,J=8.8Hz),3.84-3.94(4H,m),3.62-3.73(4H,m),2.78-2.86(1H,m),2.55(3H,s),1.71(1H,d,J=8.4Hz)。
Example 61: (E) -4- (6- (6- (4-methoxybut-2-enoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (1-methyl-1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 2(40mg) was dissolved in THF (10mL) at 0 deg.C, and (E) -4-methoxybut-2-enoic acid (12mg) and triethylamine (30mg) were added, followed by warming to room temperature and stirring for 1 hour. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (37 mg).
1H NMR(400MHz,CDCl3)δ8.63(1H,d,J=1.2Hz),8.37(1H,d,J=2.4Hz),8.25(1H,s),7.78(1H,s),7.76(1H,dd,J=8.8Hz,2.4Hz),7.68(1H,s),7.38(1H,d,J=1.2Hz),6.88(1H,dt,J=15.6Hz,4.0Hz),6.65(1H,d,J=8.8Hz),6.16(1H,dt,J=15.6Hz,2.0Hz),4.64-4.72(2H,m),4.17(1H,d,J=12.0Hz),4.06-4.09(2H,m),3.98(3H,s),3.88-3.91(2H,m),3.64-3.71(1H,m),3.39(3H,s),2.78-2.84(1H,m),1.73(1H,d,J=8.8Hz)。
Example 62: (E) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (6- (4-methoxybut-2-enoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (10mL) at 0 deg.C, and (E) -4-methoxybut-2-enoic acid (12mg) and triethylamine (30mg) were added, followed by warming to room temperature and stirring for 1 hour. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (39 mg).
1H NMR(400MHz,CDCl3)δ8.70(1H,d,J=1.2Hz),8.38(1H,d,J=2.4Hz),8.29(1H,s),8.13(1H,s),7.96(1H,s),7.76(1H,dd,J=8.8Hz,2.4Hz),7.39(1H,d,J=1.6Hz),7.25(1H,t,J=60.4Hz),6.89(1H,dt,J=15.2Hz,4.0Hz),6.64(1H,d,J=8.8Hz),6.16(1H,dt,J=15.2Hz,2.0Hz),4.64-4.72(2H,m),4.18(1H,d,J=10.8Hz),4.06-4.09(2H,m),3.88-3.92(2H,m),3.67(1H,d,J=10.8Hz),3.39(3H,s),2.78-2.84(1H,m),1.74(1H,d,J=8.8Hz)。
Example 63: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (4- ((6- (methylsulfonyl) pyridin-3-yl) methyl) piperazin-1-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 24(42mg) was dissolved in THF (10mL) at 0 deg.C, and 6- (methylsulfonyl) nicotinaldehyde (37mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (25 mg).
1H NMR(400MHz,CDCl3)δ8.72(1H,s),8.70(1H,d,J=1.6Hz),8.36(1H,d,J=2.4Hz),8.29(1H,s),8.13(1H,s),8.07(1H,s),8.02(1H,d,J=7.2Hz),7.96(1H,s),7.75(1H,dd,J=9.2Hz,2.4Hz),7.40(1H,d,J=1.6Hz),7.25(1H,t,J=60.4Hz),6.78(1H,d,J=8.8Hz),3.64-3.74(6H,m),3.25(3H,s),2.58-2.64(4H,m)。
Example 64: 6- (3, 3-Difluoroazetidin-1-yl) -4- (6- (6- (3- (methylsulfonyl) benzyl) -3, 6-diazabicyclo [3.1.1] Heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 9(64mg), 3-difluorotrimethylene imine hydrochloride (26mg), tris (dibenzylideneacetone) dipalladium (9mg), (±) -2, 2 '-bis (diphenylphosphino) -1, 1' -binaphthyl (12mg), and cesium carbonate (98mg) were successively added to a flask containing toluene (20mL), and the reaction flask was replaced with nitrogen three times. Heat to 110 ℃ and stir overnight. Cooled to room temperature, filtered, the filter cake was washed with dichloromethane, the filtrates were combined and concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (29 mg).
1H NMR(400MHz,CDCl3)δ8.38(1H,d,J=2.4Hz),8.19(1H,s),7.98(1H,s),7.82(1H,d,J=8.0Hz),7.77-7.80(2H,m),7.69(1H,d,J=6.8Hz),7.52(1H,t,J=8.0Hz),6.75(1H,d,J=2.0Hz),6.69(1H,d,J=9.2Hz),4.31(4H,t,J=11.6Hz),3.78-3.88(4H,m),3.72(2H,s),3.58-3.68(2H,m),3.06(3H,s),2.73-2.82(1H,m),1.69(1H,d,J=8.4Hz)。
Example 65: 4- (6- (6- (3- (methylsulfonyl) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (3-hydroxy-3-methylazepin-1-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 9(64mg), 3-methyl-3-acridinium alkoxide (27mg), tris (dibenzylideneacetone) dipalladium (9mg), (±) -2, 2 '-bis (diphenylphosphino) -1, 1' -binaphthyl (12mg), and cesium carbonate (98mg) were successively added to a flask containing toluene (20mL), and the reaction flask was replaced with nitrogen three times. Heat to 110 ℃ and stir overnight. Cooled to room temperature, filtered, the filter cake was washed with dichloromethane, the filtrates were combined and concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (21 mg).
1H NMR(400MHz,CDCl3)δ8.37(1H,d,J=2.4Hz),8.15(1H,s),7.98(1H,s),7.81(1H,d,J=7.6Hz),7.78(1H,dd,J=8.8Hz,2.4Hz),7.71(1H,d,J=2.0Hz),7.67(1H,d,J=8.0Hz),7.51(1H,t,J=8.0Hz),6.74(1H,d,J=2.0Hz),6.68(1H,d,J=8.8Hz),3.91(2H,d,J=8.0Hz),3.77-3.87(6H,m),3.73(2H,s),3.58-3.66(2H,m),3.06(3H,s),2.72-2.79(1H,m),1.67(1H,d,J=9.2Hz),1.66(3H,s)。
Example 66: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (6- ((5- (methylthio) pyridin-2-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (10mL) at 0 deg.C, and 5- (methylthio) pyridine-2-carbaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (31 mg).
1H NMR(400MHz,CDCl3)δ8.74(1H,s),8.45(1H,d,J=2.4Hz),8.43(1H,s),8.32(1H,s),8.15(1H,s),7.98(1H,s),7.86(1H,dd,J=8.8Hz,2.4Hz),7.76(1H,d,J=8.0Hz),7.43(1H,s),7.35(1H,d,J=8.0Hz),7.26(1H,t,J=60.4Hz),6.75(1H,d,J=8.8Hz),4.38(2H,d,J=5.6Hz),3.99(2H,s),3.89(4H,s),3.24-3.32(1H,m),2.56(3H,s),1.86(1H,d,J=10.4Hz)。
Example 67: 6- (3, 3-Difluoroazetidin-1-yl) -4- (6- (6- (2- (methylsulfonyl) benzyl) -3, 6-diazabicyclo [3.1.1] Heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 20(64mg), 3-difluorotrimethylene imine hydrochloride (26mg), tris (dibenzylideneacetone) dipalladium (9mg), (±) -2, 2 '-bis (diphenylphosphino) -1, 1' -binaphthyl (12mg), and cesium carbonate (98mg) were successively added to a flask containing toluene (20mL), and the reaction flask was replaced with nitrogen three times. Heat to 110 ℃ and stir overnight. Cooled to room temperature, filtered, the filter cake was washed with dichloromethane, the filtrates were combined and concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (19 mg).
1H NMR(400MHz,CDCl3)δ8.39(1H,d,J=2.0Hz),8.18(1H,s),8.09(1H,d,J=8.0Hz),7.76-7.79(2H,m),7.43-7.60(3H,m),6.75(1H,d,J=2.0Hz),6.72(1H,d,J=8.8Hz),4.31(4H,t,J=11.6Hz),4.06-4.19(2H,m),3.90-3.99(2H,m),3.76-3.88(2H,m),3.59-3.71(2H,m),3.34(3H,s),2.52-2.72(1H,m),1.71(1H,d,J=9.2Hz)。
Example 68: 4- (6- (6- (4- (methylsulfinyl) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (10mL) at 0 deg.C, and 4-methylsulfinylbenzaldehyde (34mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (32 mg).
1H NMR(400MHz,CDCl3)δ8.72(1H,s),8.44(1H,d,J=2.4Hz),8.31(1H,s),8.14(1H,s),7.97(1H,s),7.82(1H,dd,J=8.8Hz,2.4Hz),7.58-7.64(4H,m),7.43(1H,d,J=1.2Hz),7.25(1H,t,J=60.4Hz),6.72(1H,d,J=8.4Hz),3.83-3.98(4H,m),3.79(2H,s),3.63-3.73(2H,m),2.82-2.92(1H,m),2.72(3H,s),1.73(1H,d,J=9.2Hz)。
Example 69: 6- (1-difluoromethyl-1H-pyrazol-4-yl) -4- (6- (8- (4- (methylsulfonyl) benzyl) -3, 8-diazabicyclo [3.2.1] oct-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 22(45mg) was dissolved in THF (15mL) at 0 deg.C, 4-methylsulfonylbenzaldehyde (37mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extracts were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 15: 1 (V: V)) to give the title compound (30 mg).
1H NMR(400MHz,CDCl3)δ8.70(1H,d,J=1.2Hz),8.36(1H,d,J=2.8Hz),8.29(1H,s),8.12(1H,s),7.96(1H,s),7.92(2H,d,J=8.0Hz),7.74(1H,dd,J=8.8Hz,2.8Hz),7.67(2H,d,J=8.0Hz),7.40(1H,s),7.25(1H,t,J=60.4Hz),6.68(1H,d,J=8.8Hz),3.91(2H,d,J=11.2Hz),3.74(2H,s),3.35(2H,s),3.26(2H,d,J=11.2Hz),3.07(3H,s),2.04-2.10(2H,m),1.78-1.85(2H,m)。
Example 70: 4- (5- (6- (4- (methylsulfonyl) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyrazin-2-yl) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 23(43mg) was dissolved in THF (15mL) at 0 deg.C, 4-methylsulfonylbenzaldehyde (37mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 15: 1 (V: V)) to give the title compound (17 mg).
1H NMR(400MHz,CDCl3)δ8.74(1H,d,J=1.6Hz),8.57(1H,d,J=1.6Hz),8.35(1H,s),8.28(1H,d,J=1.6Hz),8.16(1H,s),7.99(1H,s),7.90(2H,d,J=8.8Hz),7.67(1H,d,J=1.2Hz),7.60(2H,d,J=8.0Hz),7.26(1H,t,J=60.4Hz),3.82-3.90(4H,m),3.76(2H,s),3.68(2H,d,J=12.8Hz),3.05(3H,s),2.77-2.84(1H,m),1.71(1H,d,J=9.2Hz)。
Example 71: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (6- ((6- (methylthio) pyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (10mL) at 0 deg.C, and 6- (methylthio) pyridine-3-carbaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (32 mg).
1H NMR(400MHz,CDCl3)δ8.68(1H,d,J=1.6Hz),8.31(1H,d,J=2.8Hz),8.28(1H,s),8.11(1H,s),7.94(1H,s),7.89(1H,d,J=2.8Hz),7.71(1H,dd,J=8.8Hz,2.8Hz),7.37(1H,s),7.23(1H,t,J=60.4Hz),7.03(1H,d,J=8.4Hz),6.81(1H,dd,J=8.8Hz,3.2Hz),6.56(1H,d,J=8.8Hz),4.49(2H,d,J=6.0Hz),4.06(2H,d,J=12.0Hz),3.55-3.63(2H,m),2.88-2.94(1H,m),2.49(3H,s),1.82(1H,d,J=8.8Hz)。
Example 72: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (6- ((2- (methylthio) pyridin-4-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (10mL) at 0 deg.C, and 2- (methylthio) pyridine-4-carbaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (33 mg).
1H NMR(400MHz,CDCl3)δ8.71(1H,d,J=1.6Hz),8.43(1H,d,J=2.8Hz),8.35(1H,d,J=4.8Hz),8.31(1H,s),8.13(1H,s),7.97(1H,s),7.81(1H,dd,J=8.8Hz,2.4Hz),7.43(1H,d,J=1.6Hz),7.25(1H,t,J=60.4Hz),7.23(1H,s),7.01(1H,d,J=4.0Hz),6.70(1H,d,J=9.2Hz),3.77-3.84(4H,m),3.56-3.66(4H,m),2.73-2.82(1H,m),2.56(3H,s),1.68(1H,d,J=8.8Hz)。
Example 73: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (8- ((6- (methylthio) pyridin-3-yl) methyl) -3, 8-diazabicyclo [3.2.1] oct-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 22(45mg) was dissolved in THF (15mL) at 0 deg.C, and 6- (methylthio) pyridine-3-carbaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 15: 1 (V: V)) to give the title compound (14 mg).
1H NMR(400MHz,CDCl3)δ8.69(1H,d,J=1.6Hz),8.41(1H,d,J=2.0Hz),8.35(1H,d,J=2.4Hz),8.29(1H,s),8.12(1H,s),7.95(1H,s),7.72(1H,dd,J=8.8Hz,2.4Hz),7.64(1H,dd,J=8.4Hz,2.0Hz),7.39(1H,d,J=1.6Hz),7.25(1H,t,J=60.4Hz),7.18(1H,d,J=8.4Hz),6.66(1H,d,J=9.2Hz),3.88(2H,d,J=10.4Hz),3.55(2H,s),3.28-3.34(2H,m),3.18(2H,d,J=11.2Hz),2.58(3H,s),1.98-2.08(2H,m),1.75-1.81(2H,m)。
Example 74: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (6- ((6- (methylthio) pyridin-2-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (10mL) at 0 deg.C, and 6- (methylthio) pyridine-2-carbaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (20 mg).
1H NMR(400MHz,CDCl3)δ8.71(1H,d,J=1.6Hz),8.44(1H,d,J=2.4Hz),8.31(1H,s),8.14(1H,s),7.97(1H,s),7.82(1H,dd,J=8.8Hz,2.4Hz),7.47(1H,t,J=8.0Hz),7.42(1H,d,J=1.6Hz),7.25(1H,t,J=60.4Hz),7.12-7.17(1H,m),7.06(1H,d,J=7.2Hz),6.73(1H,d,J=8.4Hz),3.53-4.03(8H,m),2.73-2.93(1H,m),2.54(3H,s),1.73(1H,d,J=8.8Hz)。
Example 75: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (4- ((6- (methylthio) pyridin-3-yl) methyl) piperazin-1-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 24(42mg) was dissolved in THF (10mL) at 0 deg.C, and 6- (methylthio) pyridine-3-carbaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (36 mg).
1H NMR(400MHz,CDCl3)δ8.69(1H,d,J=1.6Hz),8.39(1H,d,J=1.6Hz),8.36(1H,d,J=2.8Hz),8.29(1H,s),8.12(1H,s),7.96(1H,s),7.73(1H,dd,J=8.8Hz,2.8Hz),7.54(1H,dd,J=8.4Hz,2.0Hz),7.39(1H,d,J=1.6Hz),7.25(1H,t,J=60.4Hz),7.17(1H,d,J=8.4Hz),6.76(1H,d,J=8.8Hz),3.64-3.66(4H,m),3.51(2H,s),2.54-2.58(7H,m)。
Example 76: 6- (1- (methyl) -1H-pyrazol-4-yl) -4- (6- (6- ((6- (methylsulfonyl) pyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 2(42mg) was dissolved in THF (10mL) at 0 deg.C, and 6- (methylsulfonyl) nicotinaldehyde (37mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (21 mg).
1H NMR(400MHz,CDCl3)δ8.73(1H,s),8.65(1H,d,J=1.6Hz),8.44(1H,d,J=2.4Hz),8.28(1H,s),8.01-8.09(2H,m),7.82(1H,dd,J=8.8Hz,2.4Hz),7.79(1H,s),7.69(1H,s),7.42(1H,d,J=1.6Hz),6.71(1H,d,J=8.8Hz),3.99(3H,s),3.77-3.84(6H,m),3.62-3.70(2H,m),3.23(3H,s),2.73-2.82(1H,m),1.71(1H,d,J=8.4Hz)。
Example 77: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (6- ((6- (methylsulfonyl) pyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (10mL) at 0 deg.C, and 6- (methylsulfonyl) nicotinaldehyde (37mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (23 mg).
1H NMR(400MHz,CDCl3)δ8.73(1H,s),8.72(1H,d,J=1.6Hz),8.44(1H,d,J=2.4Hz),8.31(1H,s),8.14(1H,s),8.04(1H,d,J=7.6Hz),8.01(1H,dd,J=7.6Hz,1.6Hz),7.97(1H,s),7.82(1H,dd,J=9.2Hz,2.4Hz),7.43(1H,d,J=1.6Hz),7.26(1H,t,J=60.4Hz),6.71(1H,d,J=8.4Hz),3.78-3.82(4H,m),3.76(2H,s),3.60-3.69(2H,m),3.23(3H,s),2.71-2.79(1H,m),1.70(1H,d,J=8.8Hz)。
Example 78: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (6- ((5- (methylsulfonyl) pyridin-2-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (10mL) at 0 deg.C, and 5- (methylsulfonyl) pyridine-2-carbaldehyde (37mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (26 mg).
1H NMR(400MHz,CDCl3)δ9.05(1H,d,J=2.0Hz),8.71(1H,d,J=1.6Hz),8.43(1H,d,J=2.4Hz),8.30(1H,s),8.18(1H,dd,J=8.0Hz,2.4Hz),8.14(1H,s),7.97(1H,s),7.80(1H,dd,J=8.8Hz,2.4Hz),7.68(1H,d,J=8.0Hz),7.42(1H,d,J=1.6Hz),7.26(1H,t,J=60.4Hz),6.72(1H,d,J=8.8Hz),3.86-3.94(6H,m),3.61-3.71(2H,m),3.10(3H,s),2.76-2.84(1H,m),1.72(1H,d,J=8.4Hz)。
Example 79: 6- (1- (methyl) -1H-pyrazol-4-yl) -4- (6- (6- ((5- (methylsulfonyl) pyridin-2-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 2(42mg) was dissolved in THF (10mL) at 0 deg.C, and 5- (methylsulfonyl) pyridine-2-carbaldehyde (37mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (28 mg).
1H NMR(400MHz,DMSO-d6)δ9.22(1H,s),8.94(1H,s),8.64(1H,s),8.43(1H,s),8.38(1H,s),8.28(1H,d,J=7.6Hz),8.33(1H,s),7.87(1H,d,J=8.0Hz),7.78(1H,s),7.75(1H,d,J=8.4Hz),6.80(1H,d,J=8.4Hz),3.86(3H,s),3.72-3.84(6H,m),3.48-3.64(2H,m),3.29(3H,s),2.42-2.52(1H,m),1.60-1.70(1H,m)。
Example 80: 6- (1- (difluoromethyl) -1H-pyrazol-4-yl) -4- (6- (4- ((5- (methylsulfonyl) pyridin-2-yl) methyl) piperazin-1-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 24(42mg) was dissolved in THF (10mL) at 0 deg.C, and 5- (methylsulfonyl) pyridine-2-carbaldehyde (37mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (25 mg).
1H NMR(400MHz,CDCl3)δ9.01(1H,d,J=2.4Hz),8.70(1H,d,J=1.6Hz),8.37(1H,d,J=2.8Hz),8.29(1H,s),8.22(1H,dd,J=8.4Hz,2.0Hz),8.13(1H,s),7.96(1H,s),7.73-7.76(2H,m),7.40(1H,d,J=1.6Hz),7.25(1H,t,J=60.4Hz),6.79(1H,d,J=9.2Hz),3.84(2H,s),3.68-3.75(4H,m),3.13(3H,s),2.64-2.70(4H,m)。
Example 81: 4- (6- (4- (4- (methylthio) benzyl) piperazin-1-yl) pyridin-3-yl) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 24(42mg) was dissolved in THF (10mL) at 0 deg.C, and 4-methylthiobenzaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (35 mg).
1H NMR(400MHz,CDCl3)δ8.69(1H,d,J=1.6Hz),8.36(1H,d,J=2.8Hz),8.29(1H,s),8.12(1H,s),7.96(1H,s),7.73(1H,dd,J=8.8Hz,2.8Hz),7.39(1H,d,J=1.2Hz),7.27-7.31(2H,m),7.24(1H,t,J=60.4Hz),7.23(2H,d,J=8.4Hz),6.76(1H,d,J=8.8Hz),3.62-3.70(4H,m),3.53(2H,s),2.54-2.60(4H,m),2.49(3H,s)。
Example 82: 6- (1-difluoromethyl-1H-pyrazol-4-yl) -4- (6- (6- (4- (methylthio) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (20mL) at 0 deg.C, and 4-methylthiobenzaldehyde (31mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (33 mg).
1H NMR(400MHz,CDCl3)δ8.73(1H,s),8.46(1H,s),8.31(1H,s),8.15(1H,s),7.98(1H,s),7.85(1H,d,J=7.2Hz),7.47-7.55(2H,m),7.44(1H,d,J=1.2Hz),7.25-7.26(2H,m),7.24(1H,t,J=60.4Hz),6.73(1H,d,J=9.2Hz),4.13-4.37(2H,m),3.78-4.10(6H,m),3.10-3.38(1H,m),2.47(3H,s),1.80-1.90(1H,m)
Example 83: 4- (6- (6- (4-nitrobenzyl) -3, 6-diaza-bicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (1- (difluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 21(43mg) was dissolved in THF (20mL) at 0 deg.C, and 4-nitrobenzaldehyde (30mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by stirring at room temperature for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (34 mg).
1H NMR(400MHz,CDCl3)δ8.72(1H,d,J=1.6Hz),8.44(1H,d,J=2.8Hz),8.31(1H,s),8.18(2H,d,J=8.8Hz),8.13(1H,s),7.97(1H,s),7.82(1H,dd,J=8.8Hz,2.8Hz),7.58(2H,d,J=7.6Hz),7.43(1H,d,J=1.2Hz),7.26(1H,t,J=60.4Hz),6.71(1H,d,J=8.8Hz),3.73-3.88(6H,m),3.59-3.68(2H,m),2.72-2.82(1H,m),1.70(1H,d,J=9.2Hz).
Example 84: 4- (6- (6- (4- (methylsulfonyl) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (1- (trifluoromethyl) -1H-pyrazol-4-yl) pyrazolo [1, 5-a ] pyridine-3-carbonitrile
Intermediate 25(45mg) was dissolved in THF (20mL) at 0 deg.C, 4-methylsulfonylbenzaldehyde (37mg) and sodium triacetoxyborohydride (100mg) were added in this order, followed by warming to room temperature and stirring for 12 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate (50mL), extracted with dichloromethane, the extract was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by thin layer chromatography (developing solvent: dichloromethane: methanol ═ 20: 1 (V: V)) to give the title compound (33 mg).
1H NMR(400MHz,CDCl3)δ8.72(1H,d,J=1.6Hz),8.44(1H,d,J=2.4Hz),8.32(1H,s),8.13(1H,s),8.07(1H,s),7.89(2H,d,J=8.4Hz),7.81(1H,dd,J=8.8Hz,2.4Hz),7.60(2H,d,J=8.4Hz),7.41(1H,d,J=1.2Hz),6.71(1H,d,J=8.4Hz),3.78-3.84(4H,m),3.74(2H,s),3.58-3.68(2H,m),3.05(3H,s),2.72-2.78(1H,m),1.69(1H,d,J=8.4Hz)。
Biological Activity assay
RET compound bioactivity test method
1. Compound pair RETWTIn vitro enzymatic Activity assay
The compound pair RET in this patentWTInhibition of enzymatic Activity IC of50The value determination was carried out by the homogeneous time-resolved fluorescence (HTRF) method. Compounds were diluted in 100% DMSO in 5-fold gradients (7 concentrations) starting at 0.2mM, and 2. mu.L of each compound was added to 48. mu.L of reaction buffer (50mM HEPES pH7.5, 0.1mM Na)3VO4,5mM MgCl21mM DTT, 0.001% Tween 20 and 100. mu.g/ml BSA) were diluted and mixed well. 2.5. mu.L of GST-RET was added to 384 well plates (OptiPlate-384, purchased from Perkinelmer) followed by 5. mu.L of GST-RETWT(658-1114aa, final concentration 0.5nM), mixing by centrifugation, and starting the reaction by adding 2.5. mu.L of ATP (final concentration 25. mu.M) and TK Peptide Substrate mixture (final concentration 1. mu.M, purchased from Cisbio) in a total reaction volume of 10. mu.L. The 384 well plates were placed in an incubator at 23 ℃ for 2 hours, and then 5. mu.L of TKAntibody (purchased from Cisbio) and 5. mu.L of Streptavidin-XL665 (purchased from Cisbio) were added to stop the reaction. After a further 1 hour incubation in the incubator, fluorescence values (320nm excitation, detecting 665nm and 620nm emission as the enzyme activity signal) were read on Envision (purchased from PerkinElmer). RET was determined at 7 concentrations for each compoundWTThe data used for the calculation of IC of the compound using GraphPad Prism software50The value is obtained.
2. Compound pair RETV804MIn vitro enzymatic Activity assay
The compound pair RET in this patentV804MInhibition of enzymatic Activity IC of50The value determination was carried out by the homogeneous time-resolved fluorescence (HTRF) method. Compounds were diluted in 100% DMSO in 5-fold gradients (7 concentrations) starting at 0.2mM, and 2. mu.L of each compound was added to 48. mu.L of reaction buffer (50mM HEPES pH7.5, 0.1mM Na)3VO4,5mM MgCl21mM DTT, 0.001% Tween 20, 20nM SEB (purchased from Cisbio) and 100. mu.g/ml BSA). 2.5. mu.L of GST-RET was added to 384 well plates (OptiPlate-384, purchased from Perkinelmer) followed by 5. mu.L of GST-RETV804M(658-1114aa, final concentration 0.02nM), centrifuged and mixed, and then 2.5. mu.L ATP (final concentration 1.5. mu.M) and TK Peptide Substrate mixture (final concentration 1. mu.M, purchased from Cisbio) were added to start the reaction, the total reaction volume was 10. mu.L. The 384 well plates were placed in an incubator at 23 ℃ for 1 hour, and then 5. mu.L of TK Antibody (purchased from Cisbio) and 5. mu.L of Streptavidin-XL665 (purchased from Cisbio) were added to stop the reaction. After a further 1 hour incubation in the incubator, fluorescence values (320nm excitation, detecting 665nm and 620nm emission as the enzyme activity signal) were read on Envision (purchased from PerkinElmer). Each of themCompounds were tested for RET at 7 concentrations eachV804MThe data used for the calculation of IC of the compound using GraphPad Prism software50The value is obtained.
3. In vitro enzymatic Activity assay for VEGFR2 with Compounds
The compounds of this patent inhibit the enzymatic Activity of VEGFR2 IC50The value measurement was carried out by a method of homogeneous time-resolved fluorescence technique (HTRF). Compounds were diluted in 100% DMSO in 5-fold gradients starting at 1mM (7 concentrations in total), and 2. mu.L of compound was added to 48. mu.L of reaction buffer (50mM HEPES pH7.5, 0.1mM Na)3VO4,5mM MgCl2,1mM MnCl21mM DTT, 0.001% Tween 20 and 100. mu.g/ml BSA). mu.L of the mixture was added to a 384 well plate (OptiPlate-384, purchased from Perkinelmer), 5. mu.L of GST-VEGFR2 (final concentration 0.1nM) was added, the mixture was centrifuged and mixed, and 2.5. mu.L of ATP (final concentration 2.5. mu.M) and TK Peptide Substrate mixture (final concentration 1. mu.M, purchased from Cisbio) were added to initiate the reaction in a total reaction volume of 10. mu.L. The 384 well plates were placed in an incubator at 23 ℃ for 1.5 hours, and then 5. mu.L of TK Antibody (purchased from Cisbio) and 5. mu.L of Streptavidin-XL665 (purchased from Cisbio) were added to stop the reaction. After a further 1 hour incubation in the incubator, fluorescence values (320nm excitation, detecting 665nm and 620nm emission as the enzyme activity signal) were read on Envision (purchased from PerkinElmer). The signal for the enzymatic activity of VEGFR2 was measured at 7 concentrations for each compound, and the data was calculated using GraphPad Prism software to obtain the IC of the compound50The value is obtained.
4. Determination of cell proliferation Activity of Compounds in TT
Human thyroid carcinoma cell line TT cells were cultured using Ham' S F-12K medium plus 15% fetal bovine serum (FBS, available from Biological Industries, BI) and 1% penicillin/streptomycin diabody (P/S, available from Life Techology) at 37 deg.C, 5% CO2. The day before compound detection, TT cells were plated in 96-well plates (#3917, purchased from Corning) at a concentration of 5000 cells/195 μ L/well. After 24 hours the compounds were dosed starting at 10mM in 100% DMSOLine 3 times gradient dilution (total 10 concentrations), then each concentration to take 2L compound added to 48L Ham's F-12K medium dilution. mu.L of each diluted compound was added to the plated Cell suspension, the compound and cells were co-incubated in a Cell incubator for 120h (5 days), the medium was aspirated off, and 25. mu.L of Cell-Titer Glo (G7570, purchased from Promega) reagent was added and incubated for a further 5-10 minutes. Fluorescence values were then read on Envision and the data were calculated using GraphPad Prism software to obtain the IC of the compound for inhibition of cell proliferation50The value is obtained.
5. Compound proliferation activity assay in KIF5B-RET/HEK293T cells
RET fusion-type cell line KIF5B-RET/HEK293T cells constructed by lentivirus infection were cultured using DMEM medium plus 10% fetal bovine serum (FBS, purchased from Biological Industries, BI) and 1% penicillin/streptomycin diabody (P/S, purchased from Life technologies) at 37 ℃ with 5% CO2. The day before compound detection, KIF5B-RET/HEK293T cells were plated in 96-well plates (#3917, purchased from Corning) at a concentration of 2000 cells/195. mu.L/well. After 24 hours, compounds were diluted in 100% DMSO in 3-fold gradient starting at 10mM (10 concentrations total), and then 2 μ L of compound was added to 48 μ L of DMEM medium for dilution at each concentration. mu.L of each diluted compound was added to the plated Cell suspension, the compound and cells were incubated together for 72h (3 days) in a Cell incubator, and 25. mu.L of Cell-Titer Glo (G7570, purchased from Promega) reagent was added after the medium was aspirated off for another 5-10 min incubation. Fluorescence values were then read on Envision and the data were calculated using GraphPad Prism software to obtain the IC of the compound for inhibition of cell proliferation50The value is obtained.
Protein Activity and cytology data
"-" indicates no test
4. Pharmacokinetic data for compounds:
male SD rats are from Beijing Wittingle laboratory animal technology, Inc., the rats are grouped into 3 groups, and suspension of samples to be tested (5mg/kg, suspension MC 0.5%) is orally administrated. Animals were fasted overnight prior to the experiment, with the fasting time ranging from 10 hours prior to dosing to 4 hours post-dosing. Blood was collected at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose, respectively. After isoflurane anesthesia by using a small animal anesthesia machine, 0.3mL of whole blood is collected through an eyeground venous plexus, the whole blood is placed in a heparin anticoagulation tube, a sample is centrifuged at 4000rpm for 5min at 4 ℃, and the plasma is transferred to a centrifugal tube and stored at-80 ℃ until analysis. Samples from plasma were extracted using protein precipitation and the extracts were analyzed by LC/MS.
Claims (9)
1. A compound of formula (I), or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof:
wherein,
x and Y are each independently selected from CH and N;
a is selected from 5-6 membered heteroaryl, 3-12 membered heterocyclyl, -O-C1-6Alkyl, -S-C1-6Alkyl and-SO2-C1-6Alkyl, said heteroaryl and heterocyclyl being each optionally substituted by C1-6Alkyl, -CN, -OH, -NR5R6Halogen, -O-C1-6Alkyl, -S-C1-6Alkyl, or-SO2-C1-6Alkyl substitution, said C1-6Alkyl may optionally be substituted by-OH, halogen, or- (CO) N (CH)3)2Is substituted, and R5And R6Each independently selected from H and C1-6An alkyl group;
R1、R1’、R2and R2Each independently is H or C1-6Alkyl, or R1And R1' one of the compounds with R2And R2One of' may be taken together to form a bond or- (CH)2)m-;
R8Each independently selected from H, C1-6Alkyl, -O-C1-6Alkyl and- (CH)2)m-O-C1-6An alkyl group;
ar is selected from the group consisting of phenyl, pyridyl and pyrimidinyl, each of which may optionally be substituted by-O-C1-6Alkyl, -S-C1-6Alkyl, -SO-C1-6Alkyl, or-SO2-C1-6Alkyl substitution;
each m is independently selected from 1 and 2;
n is selected from 0, 1 and 2.
2. A compound according to claim 1 or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof, wherein
A is selected from the group consisting of 5-6 membered heteroaryl and 3-12 membered heterocyclyl,
the heteroaryl and heterocyclyl groups may each be optionally substituted by C1-6Alkyl, -CN, -OH, -NR5R6Halogen, -O-C1-6Alkyl, -S-C1-6Alkyl, or-SO2-C1-6Alkyl substitution, said C1-6Alkyl may optionally be substituted by-OH, halogen, or- (CO) N (CH)3)2Is substituted and
R5and R6Each independently selected from H and C1-6An alkyl group.
3. A compound according to claim 1 or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof, wherein
A is selected from 5-6 membered heteroaryl and 4-9 membered heterocyclyl, each of which may optionally be substituted with C1-6Alkyl, -CN, -OH, -NR5R6Halogen, -O-C1-6Alkyl, -S-C1-6Alkyl, or-SO2-C1-6Alkyl substitution, said C1-6Alkyl may optionally be substituted by-OH, halogen, or- (CO) N (CH)3)2Is substituted and
R5and R6Each independently selected from H and C1-6An alkyl group.
5. A pharmaceutical composition comprising a compound according to any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof, and a pharmaceutically acceptable carrier.
6. Use of a compound according to any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, polymorph or isomer thereof, for the manufacture of a medicament for the treatment of a RET-associated disease.
7. The use of claim 6, wherein the RET-associated disease is lung cancer, papillary thyroid carcinoma, medullary thyroid carcinoma, differentiated thyroid carcinoma, recurrent thyroid carcinoma, refractory differentiated thyroid carcinoma, multiple endocrine tumors of type 2A or 2B, pheochromocytoma, parathyroid hyperplasia, breast cancer, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal ganglion cell tumor, or cervical cancer.
8. The use according to claim 6, wherein the RET associated disease is RET fusion lung cancer or medullary thyroid cancer.
9. The use of claim 6, wherein the RET-associated disease is small cell lung cancer, non-small cell lung cancer, or bronchiolar lung cancer or lung adenocarcinoma.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910825867.3A CN112442028A (en) | 2019-09-03 | 2019-09-03 | RET selective inhibitor and preparation method and application thereof |
KR1020227000624A KR20220018584A (en) | 2019-07-12 | 2020-07-10 | RET selective inhibitors and methods for their preparation and use |
US17/626,318 US20220289740A1 (en) | 2019-07-12 | 2020-07-10 | Ret selective inhibitor, preparation method therefor and use thereof |
EP20840300.6A EP3998265A4 (en) | 2019-07-12 | 2020-07-10 | Ret selective inhibitor, preparation method therefor and use thereof |
CN202310986354.7A CN117865952A (en) | 2019-07-12 | 2020-07-10 | RET selective inhibitor and preparation method and application thereof |
CN202080048596.6A CN114072404B (en) | 2019-07-12 | 2020-07-10 | RET selective inhibitor and preparation method and application thereof |
JP2022501373A JP7318097B2 (en) | 2019-07-12 | 2020-07-10 | RET selective inhibitor, method of preparation and use thereof |
PCT/CN2020/101338 WO2021008455A1 (en) | 2019-07-12 | 2020-07-10 | Ret selective inhibitor, preparation method therefor and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910825867.3A CN112442028A (en) | 2019-09-03 | 2019-09-03 | RET selective inhibitor and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112442028A true CN112442028A (en) | 2021-03-05 |
Family
ID=74734253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910825867.3A Pending CN112442028A (en) | 2019-07-12 | 2019-09-03 | RET selective inhibitor and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112442028A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114072404A (en) * | 2019-07-12 | 2022-02-18 | 首药控股(北京)股份有限公司 | RET selective inhibitor and preparation method and application thereof |
-
2019
- 2019-09-03 CN CN201910825867.3A patent/CN112442028A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114072404A (en) * | 2019-07-12 | 2022-02-18 | 首药控股(北京)股份有限公司 | RET selective inhibitor and preparation method and application thereof |
CN114072404B (en) * | 2019-07-12 | 2023-09-15 | 首药控股(北京)股份有限公司 | RET selective inhibitor and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111285886B (en) | Substituted pyrazolo [1,5-a ] pyridine compounds, compositions comprising the same and uses thereof | |
EP3936509B1 (en) | Fgfr4 kinase inhibitor, preparation method therefor and use thereof | |
CN112300194A (en) | Condensed ring pyridone compounds, preparation method and application | |
CN114072404B (en) | RET selective inhibitor and preparation method and application thereof | |
WO2019134539A1 (en) | Dihydropyrazolone and pyrimidine compound, preparation method and use therefor | |
TWI644916B (en) | Pyranodipyridine compound | |
CN110950867A (en) | FGFR4 kinase inhibitor and preparation method and application thereof | |
CN112300173B (en) | Nitrogen-containing polycyclic compounds, preparation method and application | |
CN113956272A (en) | DNA-PK selective inhibitor and preparation method and application thereof | |
CN115340559A (en) | Preparation and application of SHP2 phosphatase heterocyclic inhibitor | |
JP2024516317A (en) | Preparation and application of SHP2 kinase inhibitors | |
WO2023036156A1 (en) | Dna-pk selective inhibitor, and preparation method therefor and use thereof | |
TW202204351A (en) | Compounds having a macrocyclic structure and uses thereof | |
WO2024193439A1 (en) | Shp2 phosphatase allosteric inhibitors | |
CN112442028A (en) | RET selective inhibitor and preparation method and application thereof | |
CN112209925A (en) | RET selective inhibitor and preparation method and application thereof | |
CN115850267A (en) | Bridged ring compound, preparation method and application thereof | |
CN117263959A (en) | Preparation and application of aromatic KRAS mutant protein inhibitor | |
TWI732249B (en) | FGFR inhibitor, its preparation method and application | |
CN114634521A (en) | DNA-PK selective inhibitor and preparation method and application thereof | |
CN111662292A (en) | FGFR4 kinase inhibitor and preparation method and application thereof | |
CN115073451A (en) | KRAS G12D Preparation and application of mutant protein inhibitor | |
KR20210111779A (en) | Organophosphorus-substituted compounds and therapeutic uses thereof as C-MET inhibitors | |
CN115960109B (en) | Preparation and application of condensed ring SHP2 phosphatase inhibitor | |
CN115340561A (en) | Preparation and application of SHP2 phosphatase fused ring inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210305 |